Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

The NIH confirmed Memoli’s appointment to STAT by email, despite freezing external communications. After this story was published, an NIH spokesperson forwarded a statement from him, saying ...

Though Memoli is an NIH insider, one source familiar with him noted his perspectives —particularly his opposition to Covid-19 vaccine mandates — make him more of an outsider at the agency.

The meeting was abruptly canceled Wednesday in a terse email from an NIH staff member; I soon heard from colleagues that all such committees, and other related meetings in the grant process that ...

While NIH has contributed roughly $1 million to the program over the years, funds the agency had already sent as part of a two-year contract originally set to end in 2026 could no longer be used.

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Objective Patients with increased PD-L1 + host cells in tumours are more potent to benefit from antiprogrammed death-1/programmed death ligand-1 (PD-L1) treatment, but the underlying mechanism is ...

Today Early in the fall, experts might also see more cases of respiratory syncytial virus, Dr. Geeta Sood, assistant professor of medicine and epidemiologist at Johns Hopkins Bayview Medical Center, ...